Closing the Gap for Tough-to-Treat Hepatitis C Patients

Closing the Gap for Tough-to-Treat Hepatitis C Patients

1 of 5
Next >

When sofosbuvir (Sovaldi) was approved in 2013, it was celebrated for high cure rates, but it wasn't perfect for every patient with hepatitis C. By 2016, a slew of new medicines closed the gap for the vast majority of those tough-to-treat patients, including patients with any genotype or fibrosis level, or coinfection with HIV.

When sofosbuvir (Sovaldi) was approved in 2013, it was celebrated for high cure rates, but it wasn't perfect for every patient with hepatitis C. By 2016, a slew of new medicines closed the gap for the vast majority of those tough-to-treat patients, including patients with any genotype or fibrosis level, or coinfection with HIV.

Despite the diversity of new direct-acting antivirals (DAAs), a tiny number of patients are still left behind. These include patients with genotype 3 infection plus liver damage, patients who have failed prior treatment or developed resistance and patients with decompensated cirrhosis.

At the recent Liver Meeting in Boston, Nancy Reau, M.D., section chief, Hepatology, Rush University Medical Center, presented a summary of soon-to-be-approved drugs that should work for this "handful" of groups.

Credit: ribkhan for iStock via Thinkstock.